A new era for treatment of drug-resistant tuberculosis

Affiliations

¹ Rollins School of Public Health and Emory School of Medicine, Emory University, Atlanta, GA, USA.
² Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
³ Division of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Editorial

Neel R Gandhi et al. Eur Respir J. 2018.

. 2018 Oct 4;52(4):1801350.

doi: 10.1183/13993003.01350-2018. Print 2018 Oct.

¹ Rollins School of Public Health and Emory School of Medicine, Emory University, Atlanta, GA, USA.
² Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
³ Division of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

No abstract available

Conflict of interest statement

Conflict of interest: None declared.

1. World Health Organization. Global Tuberculosis Report 2017 Report No.: WHO/HTM/TB/2017.23. Geneva,World Health Organization, 2017.
1. Falzon D, Schunemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308. - PMC - PubMed
1. Reuter A, Tisile P, von Delft D, et al. The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? Int J Tuberc Lung Dis 2017; 21: 1114–1126. - PubMed
1. Satti H, Mafukidze A, Jooste PL, et al. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho. Int J Tuberc Lung Dis 2012; 16: 468–472. - PubMed
1. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. Int J Tuberc Lung Dis 2010: 14: 275–281. - PubMed